AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Evaluation of Impaired Mobility in Chronic Illness Constitution of a Cohort

RecruitingNAAges 18 Years - 90 YearsAllUniversity Hospital, Clermont-Ferrand
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Chronic illness is a public health issue and mobility loss is frequent in this population. Among its' multiple physical and psychological consequences, increased mortality and cardiovascular morbidity seem the main concern. Therefore, the exploration of locomotor deficiencies, physical capacities and metabolism of patients with chronic illnesses constitutes a major challenge both for the treatment of causal pathologies, as well as for evaluating the impact of therapeutic interventions, the benefit of which will be an improvement in physical capacities and ultimately mobility. In view of the hypothesis of an increase in the prevalence of mobility disorders in this population, this approach is part of a logic of screening and improving the effectiveness of the care of these patients with a multidisciplinary evaluation of individual risks. The EVALMOB protocol was designed in order to try t

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Man or woman aged 18 to 90. * Patients with chronic pathology contributing to impaired mobility. * Volunteers who have given their written consent. * Affiliated to French health care system (for France) Exclusion Criteria: * Patients suffering from progressive psychiatric pathologies (active psychosis, hallucinations, etc.) or the presence of another serious unstabilized pathology (decompensated heart failure, progressive terminal cancer, etc.). * People with poorly controlled or unstable cardiovascular disease. * Major osteoarticular or neurological problems completely preventing the proper performance of the various tests. * Non-autonomous patient * Persons under guardianship, curatorship, deprived of liberty or safeguarding justice. * People excluded from another study. * Pregnant or lactating women.
๐Ÿ’Š

What it tests

  • Development of a screening algorithm designed to determine a "dysmobility" profile in patients with chronic illness.
๐Ÿ“

Where

1 site
Chu Clermont Ferrand
Clermont-Ferrand, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy